Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial - Dubertret, L.; Sterry, W.; Bos, J.D (Br J Dermatol, 2006)